entertainment
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.
The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.
advertisement
The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
With psoriasis trial ahead, Alumis raises $259 million
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
